Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 produ ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted share Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection ...

Eton Pharmaceuticals (ETON) announced that it has acquired the U.S. rights to Amglidia for the treatment of neonatal diabetes mellitus from AMMTeK. AMMTeK has conducted a post-approval study ...

Entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) from Ipsen S.A. The transaction, which was announced in October, will add a high-value biologic product to the ...

After hours: November 29 at 4:51 p.m. EST ...